IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Go back to IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
(NASDAQ: ICCM) Delayed: 1.08 +0.03 (2.86%)
Previous Close $1.05    52 Week High $ 
Open $1.05    52 Week Low $ 
Day High $1.12    P/E N/A 
Day Low $1.05    EPS $ 
Volume 92,753